COMPARISON of TWO DOSES of INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT for MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION Results of the Pan American Collaborative Retina Study Group at 24 Months

COMPARISON of TWO DOSES of INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT for MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION Results of the Pan American Collaborative Retina Study Group at 24 Months

Author Wu, Lihteh Google Scholar
Arevalo, J. Fernando Google Scholar
Berrocal, Maria H. Google Scholar
Maia, Mauricio Autor UNIFESP Google Scholar
Roca, Jose A. Google Scholar
Morales-Canton, Virgilio Google Scholar
Alezzandrini, Arturo A. Google Scholar
Diaz-Llopis, Manuel J. Google Scholar
Institution Inst Cirugia Ocular
Clin Oftalmol Ctr Caracas
Univ Puerto Rico
Universidade Federal de São Paulo (UNIFESP)
Clin Ricardo Palma
Hosp Luis Sanchez Bulnes
Univ Buenos Aires
Inst Oftalmol Valencia
Abstract Purpose: the purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity after injecting 1.25 mg or 2.5 mg bevacizumab as needed in patients with primary macular edema secondary to central retinal vein occlusion.Methods: This is an interventional, retrospective, comparative multicenter study of 86 eyes with macular edema secondary to central retinal vein occlusion that were treated primarily with intravitreal bevacizumab (44 eyes, 1.25 mg; 42 eyes, 2.5 mg). the main outcome measures were the CMT and the change of best-corrected visual acuity at 24 months.Results: All patients completed at least 24 months of follow-up. the mean number of injections per eye were 7.2 for the 1.25-mg dose group and 8.1 for the 2.5-mg dose group (P = 0.4492). At 24 months, in the 1.25-mg dose group, the logarithm of the minimal angle of resolution best-corrected visual acuity improved from baseline 0.35 +/- 6 0.57 units (P < 0.0001) versus 0.27 +/- 0.68 units for the 2.5-mg dose group (P < 0.0001). These differences were not statistically significant between both dose groups. in the 1.25-mg dose group, 25 (56.8%) eyes gained >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 6 (13.6%) lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. in the 2.5-mg dose group, 24 (57.1 %) eyes improved >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 7 (16.7%) lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. the CMT in the 1.25-mg dose group improved from 635 +/- 324 mu m to 264 +/- 160 mu m (P < 0.0001) versus 528 +/- mu m to 293 +/- 137 mu m in the 2.5-mg dose group (P < 0.0001). There was no statistically significant difference between both dose groups with regard to the CMT reduction.Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving visual acuity and reducing CMT in macular edema secondary to central retinal vein occlusion. There were no statistically significant differences between the two dose groups with regard to the number of injections, CMT, and change in visual acuity. RETINA 30:1002-1011, 2010
Keywords bevacizumab
intravitreal injection
macular edema
retinal vein occlusion
VEGF
Language English
Date 2010-07-01
Published in Retina-the Journal of Retinal and Vitreous Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 30, n. 7, p. 1002-1011, 2010.
ISSN 0275-004X (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 1002-1011
Origin http://dx.doi.org/10.1097/IAE.0b013e3181cea68d
Access rights Closed access
Type Article
Web of Science ID WOS:000279635600002
URI http://repositorio.unifesp.br/handle/11600/32695

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account